Simon Quick Advisors LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Simon Quick Advisors LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,418 shares of the medical research company’s stock after acquiring an additional 848 shares during the period. Simon Quick Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Cypress Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $253,000. Intact Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after acquiring an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $1,121,000. W.H. Cornerstone Investments Inc. boosted its position in Thermo Fisher Scientific by 25.1% during the 4th quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 576 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Thermo Fisher Scientific by 19.7% in the fourth quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company’s stock worth $217,646,000 after purchasing an additional 68,927 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE:TMO opened at $415.25 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The stock’s fifty day moving average price is $417.57 and its 200-day moving average price is $493.84. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $156.76 billion, a P/E ratio of 25.12, a PEG ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the business posted $5.11 earnings per share. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on TMO. Citigroup dropped their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. UBS Group decreased their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.